Equasens Société anonyme (0R9T.L)
EUR 44.15
(1.03%)
EUR 44.15
(1.03%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 56.65 Million EUR | -61.07% |
| 2022 | 145.52 Million EUR | 8.75% |
| 2021 | 133.81 Million EUR | 12.16% |
| 2020 | 119.3 Million EUR | 10.22% |
| 2019 | 108.24 Million EUR | 129.26% |
| 2018 | 47.21 Million EUR | 13.58% |
| 2017 | 41.57 Million EUR | 10.42% |
| 2016 | 37.64 Million EUR | 13.17% |
| 2015 | 33.26 Million EUR | 10.13% |
| 2014 | 30.2 Million EUR | 9.04% |
| 2013 | 27.7 Million EUR | -57.09% |
| 2012 | 64.56 Million EUR | -6.73% |
| 2011 | 69.22 Million EUR | 4.77% |
| 2010 | 66.07 Million EUR | 32.63% |
| 2009 | 49.81 Million EUR | -12.8% |
| 2008 | 57.13 Million EUR | -19.47% |
| 2007 | 70.94 Million EUR | 76.71% |
| 2006 | 40.14 Million EUR | 5.19% |
| 2005 | 38.16 Million EUR | 10.82% |
| 2004 | 34.44 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 14.36 Million EUR | -18.04% |
| 2024 Q2 | 14.36 Million EUR | 0.0% |
| 2023 FY | 56.65 Million EUR | -61.07% |
| 2023 Q2 | 28.52 Million EUR | 63.83% |
| 2023 Q3 | 17.52 Million EUR | -38.56% |
| 2023 Q4 | 17.52 Million EUR | 0.0% |
| 2023 Q1 | 17.41 Million EUR | -45.05% |
| 2022 Q4 | 31.69 Million EUR | 0.0% |
| 2022 Q1 | 16.66 Million EUR | -39.73% |
| 2022 FY | 145.52 Million EUR | 8.75% |
| 2022 Q2 | 27.31 Million EUR | 63.94% |
| 2021 Q2 | 26.16 Million EUR | 66.21% |
| 2021 FY | 133.81 Million EUR | 12.16% |
| 2021 Q3 | 16.82 Million EUR | -35.68% |
| 2021 Q1 | 15.73 Million EUR | -40.73% |
| 2021 Q4 | 27.64 Million EUR | 64.28% |
| 2020 Q1 | 13.44 Million EUR | -44.28% |
| 2020 Q2 | 22.88 Million EUR | 70.18% |
| 2020 FY | 119.3 Million EUR | 10.22% |
| 2020 Q3 | 15.77 Million EUR | -31.04% |
| 2020 Q4 | 26.55 Million EUR | 68.28% |
| 2019 Q2 | 20.36 Million EUR | 66.02% |
| 2019 Q4 | 24.13 Million EUR | 76.09% |
| 2019 Q1 | 12.26 Million EUR | -51.91% |
| 2019 FY | 108.24 Million EUR | 129.26% |
| 2019 Q3 | 13.7 Million EUR | -32.69% |
| 2018 Q2 | 21.71 Million EUR | 100.0% |
| 2018 FY | 47.21 Million EUR | 13.58% |
| 2018 Q4 | 25.5 Million EUR | 100.0% |
| 2018 Q3 | 12.75 Million EUR | -41.28% |
| 2018 Q1 | 10.85 Million EUR | -50.03% |
| 2017 Q1 | 9.92 Million EUR | -47.6% |
| 2017 Q3 | 10.86 Million EUR | -45.25% |
| 2017 Q4 | 21.72 Million EUR | 100.0% |
| 2017 Q2 | 19.84 Million EUR | 100.0% |
| 2017 FY | 41.57 Million EUR | 10.42% |
| 2016 Q4 | 18.93 Million EUR | 100.0% |
| 2016 FY | 37.64 Million EUR | 13.17% |
| 2016 Q2 | 18.71 Million EUR | 100.0% |
| 2016 Q3 | 9.46 Million EUR | -49.41% |
| 2016 Q1 | 9.35 Million EUR | -43.65% |
| 2015 Q1 | 8.33 Million EUR | -42.73% |
| 2015 Q3 | 8.3 Million EUR | -50.17% |
| 2015 Q2 | 16.66 Million EUR | 100.0% |
| 2015 FY | 33.26 Million EUR | 10.13% |
| 2015 Q4 | 16.6 Million EUR | 100.0% |
| 2014 Q4 | 14.54 Million EUR | 100.0% |
| 2014 Q1 | 7.83 Million EUR | -41.94% |
| 2014 FY | 30.2 Million EUR | 9.04% |
| 2014 Q2 | 15.66 Million EUR | 100.0% |
| 2014 Q3 | 7.27 Million EUR | -53.55% |
| 2013 Q3 | 6.74 Million EUR | -52.57% |
| 2013 Q1 | 7.1 Million EUR | 0.0% |
| 2013 FY | 27.7 Million EUR | -57.09% |
| 2013 Q2 | 14.21 Million EUR | 100.0% |
| 2013 Q4 | 13.48 Million EUR | 100.0% |
| 2012 FY | 64.56 Million EUR | -6.73% |
| 2011 FY | 69.22 Million EUR | 4.77% |
| 2010 FY | 66.07 Million EUR | 32.63% |
| 2009 FY | 49.81 Million EUR | -12.8% |
| 2008 FY | 57.13 Million EUR | -19.47% |
| 2007 FY | 70.94 Million EUR | 76.71% |
| 2006 FY | 40.14 Million EUR | 5.19% |
| 2005 FY | 38.16 Million EUR | 10.82% |
| 2004 FY | 34.44 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Cegedim SA | 39.99 Million EUR | -41.668% |
| Guerbet SA | 589.46 Million EUR | 90.389% |
| Nexus AG | 65.97 Million EUR | 14.124% |
| Bastide Le Confort Médical SA | 46.83 Million EUR | -20.977% |
| Revenio Group Oyj | 45.27 Million EUR | -25.135% |
| Drägerwerk AG & Co. KGaA | 1.45 Billion EUR | 96.119% |
| Sartorius Aktiengesellschaft | 1.56 Billion EUR | 96.385% |
| LNA Santé SA | 82.71 Million EUR | 31.5% |
| Siemens Healthineers AG | 8.46 Billion EUR | 99.331% |
| Medios AG | 51.93 Million EUR | -9.082% |
| Stratec SE | 64.84 Million EUR | 12.629% |